Skyclarys Ireland Reimbursement Rebuff Leaves 200 FA Patients in Limbo

Biopharma executives watching Skyclarys in Ireland are seeing a familiar European pattern: centralized EMA approval followed by national health technology assessment pushback on evidence and price. With around 200 Irish Friedreich's ataxia patients, the commercial opportunity is small, but the signal it sends about rare disease market access across Europe is significant.

On August 16, 2026, Taoiseach Micheál Martin came under political pressure to intervene in Ireland's drug reimbursement process after the Health Service Executive (HSE) Drugs Group recommended against public funding for Skyclarys, a treatment for Friedreich's ataxia. Sinn Féin leader Mary Lou McDonald wrote to the Taoiseach demanding full transparency around the assessment, the Drug Group's findings, and the basis for the non-recommendation. The dispute centers on roughly 200 people in Ireland believed to be living with Friedreich's ataxia, a rare and progressive neuromuscular condition that gradually worsens over time. A final HSE decision on whether to fund the drug is expected later in August 2026.

“

Sinn Féin leader Mary Lou McDonald wrote to the Taoiseach demanding full transparency around the assessment, the Drug Group's findings, and the basis for the non-recommendation.

The HSE Drugs Group's recommendation cited limitations and uncertainties in the available evidence and highlighted the treatment's current price as a concern. In her letter, McDonald noted that Skyclarys has been approved for use across the European Union since February 2024 and that the treatment is publicly funded or otherwise available to patients in several European countries, according to McDonald. She called for an urgent meeting between the Taoiseach and young people living with the condition. Her demand for transparency is significant because it shifts the debate from a purely clinical and cost-effectiveness assessment into the political arena, where patient voices and equity arguments carry weight.

Ireland's HTA process relies on the HSE Drugs Group to assess clinical effectiveness, comparative effectiveness, and cost-effectiveness before a reimbursement recommendation. For rare diseases such as Friedreich's ataxia, this framework is inherently strained. Small patient populations make it difficult to generate the large-scale, randomized controlled trial data that HTA bodies often prefer, while the high per-patient cost of orphan drugs raises budget-impact concerns even when the absolute number of patients is small. The HSE cited evidence limitations rather than outright inefficacy, suggesting that the available data may not have answered key questions about long-term benefit or quality-of-life impact to the satisfaction of Irish assessors. The price concern is equally typical in European rare disease reviews, where list prices for orphan therapies frequently draw scrutiny regardless of clinical value.

Politically, McDonald's intervention raises the stakes for the Taoiseach. A direct political override of an HSE recommendation would be unusual and could undermine the independence of Ireland's assessment process, but refusing to engage risks alienating patients with a severe progressive disease who see an EU-approved therapy out of reach. The letter's call for transparency could force the HSE to publish a more detailed rationale than is typical, potentially creating a precedent for future contested decisions. It may also encourage other patient groups to seek political review when HTA recommendations go against them. The final HSE decision later in August will determine whether Ireland aligns with the several European countries that already fund Skyclarys or becomes an outlier in restricting access.